2269:HKG
WuXi Biologics (Cayman) Inc
HK$48.20
arrow_downward
-0.90%(-0.44) 1 日
10月16日, 16:08:14 GMT+8 · HKD
search
すべての記号
| 記号 | 価格 | 変化 | 変化率 |
|---|
insights_auto2269 の上位の分析情報を生成しています...
始値
HK$49.98
高値
HK$50.85
安値
HK$45.82
時価総額
1984.28億
平均出来高
3042.48万
取引量
5518.23万
株価収益率
34.48
52 週高値
HK$58.00
52 週安値
HK$28.48
EPS
HK$1.40
発行済株式数
12.25億
従業員数
1万
始値
HK$49.98
高値
HK$50.85
安値
HK$45.82
時価総額
1984.28億
平均出来高
3042.48万
取引量
5518.23万
株価収益率
34.48
52 週高値
HK$58.00
52 週安値
HK$28.48
EPS
HK$1.40
発行済株式数
12.25億
従業員数
1万
ニュース記事
情報源: ウェブソース、ニュース パートナー
プロフィール
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
WuXi Biologics (Cayman) Inc について